Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 443 participants.
Also called NCT02343926
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 443 participants
- Sponsor
- Registry
-
NCT02343926
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Russia
- Registry status
- Completed
Technical summary
Registry record NCT02343926. Randomized; no masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2016-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- GEMIGLIPTIN LS15-0444
- Intervention (Drug)
- vildagliptin
- Intervention (Drug)
- metformin
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct02343926- Content hash
895f36fc3d7a22537159c0428de69ed74ea89ea3d3490a7c04fa232e8f3a07c8